Neurosense Therapeutics Ltd expected to post a loss of 24 cents a share - Earnings Preview

Neurosense Therapeutics

23/11/2023 08:08

* Neurosense Therapeutics Ltd  NRSN.OQ   NRSN.O  is expected
to report results for the period ending June 30 2023
    * 
    * ​LSEG's mean analyst estimate for Neurosense Therapeutics
Ltd is
for a loss of 24 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Neurosense
Therapeutics Ltd is $5.25​, above​ its last closing price
of $0.62. ​​​

This summary was machine generated November 23 at 08:07 GMT. 
All figures in US dollars unless otherwise stated